MRK: Portfolio transformation and pipeline advances drive long-term growth outlook

Moderna and Merck's mRNA-based cancer vaccine showed promise in preventing melanoma recurrence. This marks the first use of mRNA technology in cancer treatment, according to Moderna's chairman.

Merck (MRK) has seen an 85% return over the past year, trading near its 52-week high. GARDASIL sales, which previously declined 55% to $1.1B, have stabilized at $1.2B. Management now focuses on a $70B commercial opportunity from new products, including LIPFENDRA and sac-TMT, to offset KEYTRUDA's future exclusivity loss. Analysts question the commercial viability of these new drugs.

Merck (MRK) raised its long-term revenue target to over $70B, up from $50B, at the Wells Fargo Healthcare Conference. The company expects modest 2027 growth, with new products offsetting patent expirations and slower KEYTRUDA sales. Merck's oncology pipeline, including sac-TMT and INT, is a key growth driver. The stock is trading at $147.57 with a $364B market cap, and analysts suggest it may be slightly overvalued.

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, Intismeran Autogene, combined with Keytruda. The treatment extended survival without melanoma recurrence. MRNA stock surged 177%, MRK rose 12%. The vaccine's personalized nature and high cost may pose insurance coverage challenges. FDA approval is expected in 2027-2028. The treatment is not yet commercially priced, with estimates exceeding $150,000 per patient.

Merck's stock (MRK) is near its 52-week high, closing at $150.33 on Sept. 4, 4% below its peak. The company and Moderna (MRNA) reported positive phase III study results for their cancer therapy combo, meeting primary and key secondary endpoints. Keytruda, Merck's top-selling drug, drives over 55% of pharmaceutical sales and is key to the company's growth strategy. Merck is exploring new combinations and formulations to extend Keytruda's growth.

Merck and Moderna reported positive Phase 3 trial results for a personalized mRNA vaccine targeting melanoma, combined with Merck's Keytruda. The treatment improved recurrence-free survival, marking a potential first FDA-approved mRNA cancer therapy. The vaccine is customized using a patient's tumor DNA and RNA, teaching the immune system to target cancer cells. Costs and production time remain high, but experts anticipate advancements in manufacturing and AI-driven targeting.